Brief: Atea Pharmaceuticals Completes Patient Enrollment In Phase 3 C-Forward Trial Evaluating Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus
25/06/2026 12:23
BRIEF-Atea Pharmaceuticals Completes Patient Enrollment In Phase 3 C-Forward Trial Evaluating Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus June 25 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:
ATEA PHARMACEUTICALS COMPLETES PATIENT ENROLLMENT IN PHASE 3 C-FORWARD TRIAL EVALUATING BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS
ATEA PHARMACEUTICALS COMPLETES PATIENT ENROLLMENT IN PHASE 3 C-FORWARD TRIAL EVALUATING BEMNIFOSBUVIR AND RUZASVIR FOR TREATMENT OF HEPATITIS C VIRUS
ATEA PHARMACEUTICALS - C-FORWARD TOPLINE RESULTS EXPECTED AROUND YEAR-END 2026
ATEA PHARMACEUTICALS - C-BEYOND PHASE 3 TOPLINE RESULTS EXPECTED MID-YEAR 2026
Source text: ID:nGNXbQGBvw
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM